Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Marie-Émilie Dourthe1, Karima Yakouben2, Delphine Chaillou2

  • 1Service d'Hématologie Pédiatrique, Hôpital Universitaire Robert Debré (APHP), 75019 Paris, France; Université Paris Diderot, 75010 Paris, France.

Bulletin Du Cancer
|January 29, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caution in Interpreting Prognostic Genomic Factors in Underpowered Subgroups of Children with T-ALL.

Blood advances·2026
Same author

Persistent <i>BCR::ABL1</i>-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

HemaSphere·2026
Same author

Descriptive Epidemiology and Prognosis of Pediatric Acute Leukemia in the Afro-Descendant Population of the French West Indies and French Guiana.

Cancer medicine·2026
Same author

Increased Susceptibility to Long-Term Complications in Leukemia Survivors Who Received Hematopoietic Stem Cell Transplantation During Adolescence.

Transplantation and cellular therapy·2026
Same author

Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia.

Leukemia·2026
Same author

First-year results of the International Leukemia/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.

Haematologica·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles
This summary is machine-generated.

Chimeric antigen receptor (CAR) T-cell therapy shows promise for treating relapsed or refractory B-acute lymphoblastic leukemia (B-ALL) in children, with high response rates. Future research aims to improve CAR-T cell production and manage adverse events for broader applications.

Area of Science:

  • Oncology
  • Immunotherapy
  • Pediatric Hematology/Oncology

Background:

  • Acute lymphoblastic leukemia (ALL) is the leading childhood cancer, with significant mortality despite advances.
  • CAR T-cell therapy represents a novel immunotherapy approach targeting CD19+ B-leukemic cells.

Purpose of the Study:

  • To review current indications and future perspectives of CAR T-cell therapy in pediatric ALL.
  • To evaluate the efficacy and challenges of CAR T-cell therapy in refractory or relapsed B-ALL.

Main Methods:

  • Review of phase I-II studies on CAR T-cell therapy for pediatric B-ALL.
  • Analysis of response rates, remission persistence, and adverse events.
  • Discussion of challenges including production, cost, and CD19 negative relapses.
Keywords:
Acute leukemiaB cell lymphomaCAR T cellsChildrenEnfantsImmunotherapyImmunothérapieLeucémie aiguëLymphome B

Related Experiment Videos

Main Results:

  • CAR T-cell therapy achieved overall response rates of 60-90% in patients with second relapse or refractory B-ALL.
  • Persistent remissions and cures have been observed, suggesting potential for first-line use in high-risk cases.
  • CD19 negative relapses necessitate development of alternative strategies like bispecific CAR T-cells.

Conclusions:

  • CAR T-cell therapy offers a transformative prognosis for pediatric B-ALL.
  • Addressing challenges in production, cost, and adverse event management is crucial for widespread adoption.
  • Future directions include allogeneic CAR T-cells, improved CAR design, and application in other hematologic malignancies and solid tumors.